Clinical trial
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/…
NCT00382590 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00382590 |
|---|---|
| Title | Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients |
| Official title | A Randomized Phase II Study of the Combination of 5-Azacytidine With Valproic Acid (VPA) Versus Low-Dose Ara-C in Patients With AML/MDS Not Eligible for Other Studies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia |
| Intervention type | Drug |
| Interventions | 5-Azacytidine, Ara-C, Valproic Acid (VPA) |
| Enrollment | 11 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Sep 29, 2006 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: